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Abstract 23 
Artemisinins are peroxidic antimalarial drugs known to be very potent but chemically highly 24 
unstable; they degrade in the presence of ferrous iron, Fe(II)-heme or biological reductants.  Less 25 
documented is how this translates into chemical stability and antimalarial activity across a range of 26 
conditions applying to in vitro testing and clinical situations. Dihydroartemisinin (DHA) is studied 27 
here because it is both an antimalarial drug on its own and the main metabolite of other 28 
artemisinins. The behavior of DHA in PBS, plasma or erythrocytes lysate at different temperatures 29 
and pH ranges was examined. The antimalarial activity of the residual drug was evaluated using the 30 
chemosensitivity assay on P. falciparum, and the extent of decomposition of DHA was established 31 
through use of HPLC-ECD analysis. The role of the Fe(II)-heme was investigated by blocking its 32 
reactivity using carbon monoxide. A significant reduction in the antimalarial activity of DHA was 33 
seen after incubation in plasma and to a lesser extent in erythrocytes lysate: activity was reduced by 34 
half after 3 hours and almost completely abolished after 24 hours. Serum-enriched media also 35 
affected DHA activity. Effects were temperature and pH-dependent and paralleled the increased 36 
rate of decomposition of DHA from pH 7 upwards and in plasma.  37 
These results suggest that particular care should be taken in conducting and interpreting in vitro 38 
studies, prone as they are to experimental and drug storage conditions. Disorders such as fever, 39 
hemolysis or acidosis associated with malaria severity may contribute to artemisinins instability and 40 
reduce their clinical efficacy.   41 
42 
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Introduction 43 
Artemisinin derivatives are the most potent antimalarials available to-date; they are highly active 44 
against all Plasmodium species and parasite stages, including young gametocytes, and constitute the 45 
backbone of malaria case management, both for severe and uncomplicated malaria (as a component 46 
of ACT, artemisinin combination therapy) (1). The emergence and spread of artemisinin resistance 47 
in Southeast Asia is therefore a serious threat to malaria control (2, 3). 48 
All artemisinin derivatives share a distinctive 1,2,4-trioxane pharmacophore, which confers their 49 
antimalarial activity (the corresponding acyclic analogues lacking the endoperoxide bridge are 50 
inactive) (4, 5), but makes also these molecules particularly highly reactive and thus difficult to 51 
quantify in plasma or blood. Of the various artemisinin-type compounds in use, dihydroartemisinin 52 
(DHA), the reduced lactol derivative of artemisinin, is both an antimalarial compound on its own 53 
(currently co-formulated with piperaquine), and the main bioactive metabolite of artesunate and 54 
artemether. DHA itself is chemically fragile, and displays a marked propensity to undergo ring 55 
opening of the lactol and rearrangement under neutral conditions, leading to a new, biologically-56 
active peroxide which, in turn, rapidly decays to the inert end product deoxyartemisinin (6). Under 57 
aqueous conditions, artemisinins tend to react with labile ferrous iron and heme-Fe(II) and in 58 
certain organic solvent, such as DMSO, they degrade very quickly (7). Moreover, under 59 
physiological conditions at pH 7.4, artemisinins are also reduced by biological reductants, such as 60 
flavin cofactors (8). Artemisinin-type compounds are short-lived (depending on the route of 61 
administration, elimination half-lives range 0.67-20.2 hours), but their antimalarial activity persists 62 
without measurable drug levels (9, 10). 63 
While these characteristics are well-known, more incomplete is our understanding of how 64 
artemisinin derivatives behave in various conditions, and how this relates to their antimalarial 65 
activity. Here, we describe the effects on chemical decay and in vitro activity on cultures of 66 
exposing DHA to a range of conditions (pH, temperature, media, blood products) likely to be 67 
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relevant to the interpretation of in vitro assays and clinical use of DHA, and which could affect its 68 
overall activity.    69 
 70 
Methods 71 
In vitro cultures of P.falciparum  72 
The CQ-sensitive (D10) and the CQ-resistant (W2) strains of P.falciparum were maintained at 5% 73 
hematocrit (human type A-positive red blood cells) in RPMI 1640 (EuroClone) medium 74 
supplemented with 1% AlbuMaxII (lipid-rich bovine serum albumin) (Invitrogen), 0.01% 75 
hypoxantine (Sigma), 20mM Hepes (EuroClone), 2 mM glutamine (EuroClone). All the cultures 76 
were maintained at 37°C in a standard gas mixture consisting of 1% O2, 5% CO2, 94% N2 (11).  77 
Preparation of erythrocytes lysate 78 
Blood samples from human donors kept in citrate–phosphate–dextrose solution were obtained from 79 
AVIS Milano. Blood was centrifuged to remove plasma and leukocytes, and RBCs were washed 80 
two times with RPMI medium.   81 
One mL of 100% erythrocytes was diluted in 10 mL of PBS, pH 7.4. The suspension was then 82 
divided in two aliquots. In order to obtain carbon monoxide (CO) hemoglobin, 5 mL of PBS diluted 83 
RBCs were flushed with a gas mixture containing 2% CO, 5% CO2 and 93% nitrogen for 5 minutes. 84 
Both normal and CO-flushed erythrocytes were then lysed by a cycle of freeze–thawing at -80°C; 85 
the stable complexation of Fe(II)-heme with CO was confirmed by UV–VIS spectrophotometry, 86 
which showed the shift in absorption from 414nm of oxy-hemoglobin to 420nm of carboxy-87 
hemoglobin (HbCO) (12, 13). Erythrocytes lysates were further diluted 1:5 in PBS to perform the 88 
experiments described below.   89 
DHA preparation and incubation conditions 90 
DHA (a gift from Prof R. Haynes) was weighed and dissolved in ethanol at a concentration of 40 91 
mM. The drug was then diluted at 2 µM in PBS, plasma (inactivated at 56°C for 40 min), serum, 92 
plasma diluted in PBS, erythrocytes lysate or CO-flushed erythrocytes lysate diluted 1:5 in PBS. 93 
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Samples were then incubated at 37°C for different lengths of time (3, 6, 18 hours) in a CO2 94 
incubator. Some experiments were performed at 4°C, room temperature or 40°C. DHA was also 95 
incubated in erythrocyte lysate or in plasma in the presence of ascorbic acid (Sigma-Aldrich) (0.5-1 96 
mM) dissolved in PBS at 100 mM and then diluted to the desired concentrations directly in the 97 
incubation mixtures. Artesunate (a gift from Prof R. Haynes) and chloroquine (Sigma-Aldrich) were 98 
dissolved at 40 mM in DMSO or water, respectively, and then diluted to 2 µM in the conditions 99 
described above. 100 
For the experiments performed at different pHs, phosphate buffer at pHs 7.2, 7.4 and 7.6 was 101 
prepared using different ratio of NaH2PO4 and Na2HPO4 and pHs were measured using a pHmether.  102 
The activity of each DHA preparation was then determined by the semi-automated pLDH assay 103 
(Freedom Evo 75, Tecan Italia, Srl). Briefly, samples containing DHA were diluted in complete 104 
medium at 100 nM DHA concentration, placed in 96 wells flat-bottom microplates (Costar) and 105 
serially diluted. Control (fresh DHA, artesunate, and chloroquine –CQ) were dissolved in DMSO or 106 
water at 10 mg/ml and then diluted to the desired concentration in complete medium. Asynchronous 107 
cultures with parasitemia of 1–1.5% and 1% final hematocrit were aliquoted into the plates and 108 
incubated for 48 h at 37°C. Parasites growth was determined spectrophotometrically (OD650) by 109 
measuring the activity of the parasite lactate dehydrogenase (pLDH), according to a modified 110 
version of Makler’s method in control and drug-treated cultures (14). Antimalarial activity was 111 
determined as concentration of drugs inducing 50% of growth inhibition (IC50). Three independent 112 
experiments were performed and each one in duplicate.  113 
Measurement of DHA half-life at different pH and in plasma 114 
Chromatographic determinations were performed by high-performance liquid chromatography 115 
(HPLC) grade acetonitrile by electrochemical detection operating in the reductive mode at -1000 116 
mV in an oxygen free environment (HPLC-ECD BAS 200A, Bioanalytical System, Inc., West 117 
Lafayette, IN, USA). Chromatographic separations were obtained on a Nucleosil C18 stainless steel 118 
column 250 x 4.6mm I.D., 5 µ particle size (Phenomenex, Torrance, USA).  119 
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Buffer solutions of varying species with pH ranges of 1.0 to 8.6 (pH <2 hydrochloric acid buffer, 120 
pH 2.0 – 4.5 phthalate buffer, pH 6.0 – 7.4 phosphate buffer, pH 8.6 borate buffer) were prepared at 121 
a constant total buffer species concentration of 0.2M and ionic strength, µ = 0.5 by adding sodium 122 
chloride. Sample solutions of DHA at 20, 30, 40 and 50 mg/L were prepared by using a specific 123 
volume of a 1.0 mg/mL DHA stock solution (in ethanol) and make up to 100mL with buffer 124 
(preheated to 37oC). The DHA stock solution was prepared in ethanol because of the poor solubility 125 
of DHA in buffer solutions. The resulting mixture was sealed to prevent water evaporation and 126 
maintained at the appropriate temperature in a thermostat water bath (Memmert water bath model 127 
W270, Schwabach, Germany). The temperature was kept at 37 ± 0.1ºC. At appropriate time 128 
intervals, 500 µL aliquots of the reaction mixture were removed from the reaction vessel, pipetted 129 
into test tubes, sealed and immediately stored in a -70ºC freezer and analysed as quickly as possible. 130 
At the time of analysis, samples were removed from the freezer and thawed. 100µL of the internal 131 
standard stock solution (40mg/L) prepared in ethanol:water (50:50 v/v) and 400µL of ethanol:water 132 
(50:50 v/v) was added into the sample test-tube containing 500 µL sample and vortex mixed. A 133 
fixed volume (20 µL) of these samples was assayed chromatographically to determine the 134 
concentrations of DHA and artemisinin. This procedure was used for all pH values. 135 
To determine the kinetics of decomposition of DHA in plasma, 40 microlitres of DHA (50ng/µL) 136 
solution in ethanol-water (50:50 v/v) was spiked in a salinized glass culture tube containing 500 µL 137 
plasma and 460 µL of phosphate buffer (pH 7.4) to obtain a final concentration of 2000ng/0.5mL 138 
plasma. The total reaction volume was 1mL and the incubation was carried out at 37 ± 0.1oC. At 139 
appropriate time intervals (0, 0.5, 1, 1.5, 2, 2.5 and 3 hours) the samples were withdrawn and 140 
immediately stored in -70oC freezer until analysis by HPLC-ECD. At the time of analysis, samples 141 
were removed from the freezer and thawed at 4oC. 20µL of the internal standard stock solution 142 
(40mg/L) was added and extracted, according to the method of Navaratnam et al(15), and 143 
subsequently analyzed by HPLC-ECD. 144 
Statistical analysis 145 
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Data were expressed as mean ± SD and analyzed using two-tailed Student’s t test with a level of 146 
significance of p < 0.05. 147 
 148 
Results 149 
Blood components reduced DHA effectiveness against P.falciparum  150 
To investigate the effects of blood components on DHA activity against P. falciparum,  DHA (2 151 
µM) was incubated for 18 hours at 37°C in PBS, erythrocyte lysate or plasma. The role of 152 
Fe(II)heme in DHA activity was investigated by flushing erythrocytes with CO, which firmly binds 153 
Fe(II)heme (16), thus inhibiting its reactivity. Fresh DHA, weighed and dissolved immediately 154 
before the assay, was used as control. As shown in figure 1A, DHA activity was reduced after 155 
incubation in all the conditions used. In particular, DHA activity was almost completely lost after 156 
incubation in plasma and to a lesser extent in erythrocytes lysate; the presence of CO partially 157 
restored activity. When human serum was used instead of human plasma, the results were 158 
comparable, indicating that the reduction in drug activity could not be ascribed to anticoagulants. 159 
When DHA was incubated in plasma serially diluted in PBS, the reduction in DHA activity was 160 
inversely related to the dilution (Figure 1B). 161 
To verify if the loss in drug activity was related to the peroxide moiety, artesunate (extensively 162 
converted to DHA(17)) and chloroquine (a 4-aminoquinoline) were incubated in PBS or in the 163 
blood components for 18 hours before testing their activity on parasite. Table 1 shows the mean 164 
IC50 of the drugs and the ratio between the IC50 of the fresh drug and the IC50 of the drug after 165 
incubation in blood components. Chloroquine was only marginally affected (the 7-20 % drop in 166 
activity across the different conditions was not statistically significant). The effects of PBS and 167 
HbCO on artesunate were mild, but marked reductions were observed in plasma, though 168 
proportionally less than for DHA.  169 
DHA activity was also reduced after 18h incubation in the serum-enriched medium usually used for 170 
in vitro cell or parasite cultures, namely RPMI containing 10% fetal calf serum or 1% AlbuMax 171 
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(Table 2). DHA activity was partially preserved at 4°C or at room temperature. These temperatures 172 
were chosen to reproduce common conditions for handling drugs in in vitro screening assays.  173 
DHA stability at different pH and in plasma 174 
Table 3 provides the values of kobs and t 1/2 at the various pH values and at 37oC. The pH rate profile 175 
curve for DHA given in Figure 2 is U shaped, which is typical of reactions that are susceptible to 176 
specific acid-base catalysis. Assuming there is no appreciable catalytic effect of the buffer systems 177 
used in the study, the observed rate constant generally obeys the equation kobs = kH+ [H+]m when the 178 
catalysis is largely by hydrogen ions, and kobs = kOH- [OH]n when catalysis is mainly by hydroxyl 179 
ions, where kH+ is the rate constant for hydrogen-ion-catalyzed reaction, kOH- is the rate constant for 180 
the hydroxyl-ion-catalyzed reaction and m and n are constants. The values of kH+, m, kOH- and n 181 
were obtained by plotting log kobs versus pH in the low (pH < 2.2) and high (pH >7) regions and 182 
were 1.62x10 -3 Lmol -1s-1,  –1.19, 1.43x10-11 Lmol-1 s-1 and 0.86, respectively.  183 
In plasma, the rate constant, k for degradation was higher than that of the corresponding buffer 184 
solution at pH 7.4: 8.55 x 10-5s-1  vs. 3.48 x 10-5s-1 , respectively. The corresponding t 1/2 were 5.5 185 
hours (332 min) and 2.3 hours (135 min).  186 
DHA decay followed pseudo first-order kinetics at constant temperature and ionic strength over the 187 
pH range 1.0 – 8.6 (beyond which the reaction was rapid and the procedure unsuitable for 188 
determining the rate constant). This pseudo first-order dependence is illustrated in Figure 4, which 189 
shows that the log concentration versus time plots are linear and is confirmed by the absence of a 190 
significant influence of drug concentration on kobs or  t1/2 in the range 20 mg/L (k = 6.22x10-5 ± 191 
2.08x10-7 sec-1; t ½  11138± 37 sec) – 50 mg/L (6.74x10-5 ± 2.08x10-6 sec-1; t ½ 10290 ± 312 sec). 192 
 193 
Antiplasmodial DHA activity depends on temperature and pH  194 
DHA was incubated in plasma at 37°C or 40°C (to mimic increased body temperature during a 195 
malaria attack) for 3 and 6 hours. Longer incubation was not considered since DHA activity was 196 
completely lost after 18 hours in plasma (see Fig1A). Table 4 shows a time-dependent loss of DHA 197 
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activity from 3 to 6 hours incubation in plasma at 37°C and 40°C; the residual activity was <50% 198 
and decreased to 15% after 3 or 6 hours of incubation, respectively (Figure 3a), in agreement with 199 
DHA half-life calculated in plasma (2.3 hours). The loss of activity was increased by higher 200 
temperature (40°C).   201 
To better investigate small variations of pH around the physiological 7.4, DHA was incubated in 202 
phosphate buffer at pH 7.2, 7.4 and 7.6 at 37°C for 6 hours, showing a progressive reduction of 203 
activity from pH 7.2 to 7.6 (Table 5). A high degree of correlation was found between IC50 and Kobs 204 
in the pH 7.2 - 7.6 range, clearly indicating that the loss in DHA activity is related to increased 205 
degradation (Figure 3b). 206 
Reductants promote DHA degradation 207 
The presence of the antioxidant ascorbic acid (or N-acetylcysteine, data not shown) in the RBC 208 
lysate strongly reduced DHA activity in the presence of HbO (Table 6). CO binding to Fe(II)-heme 209 
conferred partial protection against this loss in activity. Instead, adding ascorbic acid to plasma had 210 
no effects on DHA activity. Three hours incubation times were used in these experiments as DHA 211 
activity dropped rapidly in the presence of ascorbic acid.  212 
 213 
Discussion 214 
The implications of the findings of this paper cover the use of DHA in the clinics, the measurement 215 
of levels in biological fluids, and in vitro sensitivity assays. We detected a drop in DHA activity 216 
upon P. falciparum in vitro after incubation in different conditions which broadly mimic 217 
physiological and pathological situations occurring during malaria infection. We also identified 218 
conditions of in vitro assays which are likely to influence the interpretation of DHA in vitro data. 219 
The dose of DHA used in the experiments (2 µM) is biologically relevant since it is in the range of 220 
maximal concentration (Cmax) detected in the plasma of adults patients after oral or parenteral 221 
administration of artesunate (18).  222 
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Consistent results were obtained in this paper between experiments measuring chemical degradation 223 
and biological activity, confirming that loss in activity and  decomposition of DHA are related. 224 
Both the chemical degradation and the corresponding reduction in biological activity are pH, time 225 
and temperature dependent. Of all the conditions tested, plasma (and serum, data not shown) had 226 
the largest effect on drug activity.  227 
Changes in DHA activity on P. falciparum were consistent with in vitro degradation rates which 228 
were tested over pH values ranging from highly acidic to slightly basic as well as in human plasma. 229 
DHA appears to be more prone to decomposition than artesunate around neutral pH and in plasma. 230 
Artesunate itself is rapidly and extensively transformed into DHA in vivo (17). In experimental 231 
conditions, artesunate half-life (t ½) at pH 7.4 is 10.8 hours and in plasma 7.3 hours (Olliaro and 232 
Navaratnam, unpublished observation), compared to 5.5 and 2.3 hours for DHA. This means that 233 
after 18 hours’ incubation of artesunate, assuming a linear decay throughout, only about 31% and 234 
18% of the drug will still be artesunate itself (the rest being DHA and its further degradation 235 
products (6)). This translates in 89% of the activity of the parent drug remaining after incubation in 236 
PBS for 18 hours for artesunate vs. 38% for DHA; the respective values in plasma are 17% for 237 
artesunate and 0% for DHA.  238 
Here we show that DHA is stable within the pH range 2 to 6 (conditions which apply to the stomach 239 
and small intestine where the drug is absorbed), while pH lower than 2 and higher than 6 promote 240 
DHA degradation. This U-shaped pH profile is typical of reactions that are susceptible to specific 241 
acid-base catalysis. The reaction follows pseudo-first order kinetics with a log-linear decay over 242 
time up to pH 8.6.  243 
A possible limitation of this study is that it measured the disappearance of DHA but did not 244 
characterize the formation and disappearance of other species, notably the rearranged bio-active 245 
peroxyhemiacetal metabolite  (6). The parallel between chemical decay and biological activity on P. 246 
falciparum should therefore allow for all the bio-active species.  247 
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To mimic conditions that may occur in vivo, we incubated DHA in phosphate buffer around the 248 
physiological pH (7.2, 7.4, 7.6) and found a high correlation between the speed at which 249 
degradation occurs and loss in activity. DHA was relatively more stable and more active at pH 7.2, 250 
in conditions such as those encountered in malaria-related acidosis; for instance, compared to pH 251 
7.4, at pH 7.2 the DHA t ½ in buffer would be ca. one-third longer (8.1 hours instead of 5.5 hours), 252 
and potency ca. one-fourth higher (IC50 7.8 vs. 10.6). This difference between the t ½ and IC50 ratios 253 
is likely accounted for by the presence of other bioactive species, such as the above-mentioned 254 
peroxyhemiacetal metabolite. However, if acidosis might drive the equilibrium one way, 255 
intravascular hemolysis could compromise DHA activity by liberating Fe(II)-heme. Hemolysis, 256 
another condition related to severe manifestations of malaria,  was reproduced in the present work 257 
by incubating  the drug in erythrocytes lysate. Previous studies show that Fe(II), but not Fe(III) can 258 
decompose artemisinin (19, 20), and that peroxidic antimalarials are stable in the presence of 259 
hemoglobin but react with free heme (21). In this work, further evidence of the role of Fe(II)-heme 260 
is that flushing RBC lysate with CO, which tightly binds Fe(II)-heme inhibiting its reactivity, 261 
moderated the effects on DHA activity. These data are in agreement with a previous study, wherein 262 
it was observed that the activity of artemisinin antimalarials is increased when parasites were grown 263 
in the presence of CO, and that artemisinins are unaffected by carboxy-hemoglobin or CO-heme, 264 
but are decomposed by Fe(II)-hemoglobin or Fe(II)-heme (13, 22). Thus, we can expect DHA to be 265 
degraded faster and therefore be less active, when intravascular hemolysis occurs. Also supporting 266 
the role of Fe(II)-heme is the finding that the introduction of ascorbic acid, a reducing agent, during 267 
DHA incubation in normal erythrocytes lysate (but not in CO-erythrocytes lysate or plasma in the 268 
absence of hemolysis), further reduces DHA activity. Ascorbic acid would reduce the pool of 269 
Fe(III) to Fe(II), which then in turn would degrade DHA.  270 
The results of this study have also practical methodological implications for pharmacokinetic and in 271 
vitro drug assays. They support the idea of using methods for artemisinin determination in blood 272 
that employ oxidizing agents (i.e., potassium dichromate or hydrogen peroxide) to stabilize blood 273 
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and prevent degradation (23, 24). In addition, it is important to consider factors that could favor 274 
hemolysis and exposure to heme products. These results are also important for the conduct and 275 
interpretation of in vitro assays; DHA activity dropped after incubation in the media containing fetal 276 
calf serum or AlbuMax, which are routinely used for in vitro culture studies. It is therefore 277 
important to use the drug immediately after preparation or keep the drug in conditions that prevent 278 
loss of activity (e.g. stock solution in ethanol at 4°C (25)).  279 
Finally, DHA decomposition may bear on the rise of artemisinin resistance; chemical 280 
decomposition, with consequent decay in antimalarial activity and parasites being exposed to 281 
suboptimal DHA concentrations, could select for drug-resistant parasites in patients treated with 282 
DHA itself or artemisinin derivatives metabolized to DHA. 283 
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Figure legends 369 
Figure 1. DHA (2µM) was incubated for 18 hours in the presence of PBS, normal (HbO) and CO-370 
flushed (HbCO) RBC lysate and plasma (a) or in the presence of plasma diluted with PBS at 371 
different plasma: PBS ratios (b). P. falciparum (W2 strain) cultures were then exposed to the drug 372 
for 48 hours. Fresh DHA dissolved immediately before the assay was used as control. A 373 
representative experiment is shown. 374 
Figure 2. pH degradation rate profile of DHA. K is the rate constant per second.  375 
Figure 3. Residual activity of DHA (IC50 of fresh DHA/ IC50 of DHA after incubation) in PBS or in 376 
plasma at different temperatures and times (a). Correlation-regression of Kobs (degradation rate 377 
constant per second) and biological activity (IC50 in nM) in the pH range 7.2 – 7.6 (b) 378 
Figure 4. Observed pseudo first-order plots for the hydrolysis at 37oC. Log DHA concentration 379 
over time (sec) 380 
381 
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Table1. Antiplasmodial activity of DHA, artesunate or chloroquine following exposure to different 382 
conditions  383 
 DHAb  
IC50 (nM) 
Ratio 
IC50 fresh 
DHA/ 
IC50 DHA 
after 
incubation 
Artesunateb 
IC50 (nM) 
Ratio 
IC50 fresh 
Artesunate/
IC50 
Artesunate 
after 
incubation 
Chloroquineb  
IC50 (nM) 
Ratio 
IC50 fresh 
Chloroquine/
IC50 
Chloroquine 
after 
incubation 
Fresh 
druga 
2.6 ± 1.1  4.7 ± 1.2  436.2 ± 97  
PBS 7.6 ± 4* 0.34 5,3 ± 1.5 0.87 548.8 ± 55 0.79 
HbO 19.4 ± 8.5* 0.13 15.4 ± 6.4* 0.3 551.7 ± 31 0.79 
HbCO 11.9 ± 5.3* 0.22 7.8 ± 0,9* 0.59 544.2 ± 35 0.8 
Plasma >200  34.9 ± 1.7** 0.13 464.5 ± 107 0.93 
a Drugs (2 µM) were used as fresh preparations or incubated for 18 hours at 37°C in PBS, normal or 384 
CO flushed RBC lysate (HbO or HbCO) and plasma. P. falciparum (W2 strain) cultures were then 385 
exposed to the drugs for 48 hours and the parasite viability was assessed by the pLDH method. 386 
bData are the mean IC50 (nM) ± SD of three different experiments in duplicate 387 
* p<0.05 vs fresh drug; ** p<0.01 vs fresh drug 388 
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Table 2. DHA activity after incubation in commonly-used serum-enriched cell culture media  389 
 IC50 (nM) b 
 4°C room temperature 37°C 
Fresh DHAa 2.73 ± 1.5   
RPMI-AlbuMax 7.04 ± 1.7 9.73 ± 0.8* 118.1± 49* 
RPMI-FBS 6.23 ± 1.7 10.6 ± 1.4* 108.6 ± 10** 
aDHA (2µM) was used as fresh preparation or incubated for 18 hours in a medium containing 10% 390 
FBS or 1% AlbuMax at three different temperatures. P. falciparum (W2 strain) cultures were then 391 
exposed to the drugs for 48 hours and the parasite viability was assessed by the pLDH method. 392 
bData are the mean IC50 (nM) ± SD of three different experiments in duplicate 393 
* p<0.05 vs fresh DHA; ** p<0.01 vs fresh DHA 394 
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Table 3. Observed degradation rate constants (kobs) in sec–1 and half-lives (t 1/2 in minutes and hours) 395 
of DHA at various pH  at 37 ± 0.1oC 396 
 pH k(s-1) t 1/2(min) t 1/2 (hrs) 
  
 
 
 
 
DHA 
1 1.02x10-4 113 1.9 
1.2 6.22x10-5 186 3.1 
1.5 2.52x10-5 458 7.6 
2.2 3.85x10-6 3001 50.0 
3 7.76x10-7 14887 248.1 
6 1.32x10-6 8752 145.9 
7 1.62x10-5 713 11.9 
7.4 3.48x10-5 332 5.5 
8 1.04x10-4 111 1.9 
8.6 3.99x10-4 29 0.5 
Plasma 8.55x10-5 135 2.3 
397 
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Table 4. Effect of short incubation times and higher temperature on DHA activity 398 
 IC50 (nM) b 
 3 hours 6 hours 
 37°C 40°C 37°C 40°C 
Fresh DHAa 2.4 ± 0.5    
PBS 3.31 ± 1.3 7 ± 1.9  4.3 ± 2.1 ND 
Plasma 6.13 ± 1.9* 12.8 ± 1.8* 10.08 ± 4.1* 38.2 ± 3.5* 
aDHA (2µM) was used as fresh preparation or incubated for 3 or 6 hours in PBS or in plasma at 399 
37°C or 40°C. P. falciparum (W2 strain) cultures were then exposed to the drugs for 48 hours and 400 
the parasite viability was assessed by the pLDH method. 401 
bData are the mean IC50 (nM) ± SD of three different experiments in duplicate 402 
*p< 0.05 vs fresh DHA403 
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Table 5: Influence of pH in the range 7.2 – 7.6 on antiplasmodial DHA activity 404 
 IC50 
IC50(nM) b 
Ratio IC50 
fresh 
DHA/IC50 
DHA after 
incubation 
Fresh DHAa 2.8 ± 0.7  
pH 7.2 7.79 ± 1** 0.36 
pH 7.4 10.6 ± 1.1** 0.26 
pH 7.6 14.3 ± 3.5* 0.20 
aDHA (2µM) was used as fresh preparation or incubated for 6 hours at pH values 7.2 – 7.6. P. 405 
falciparum (W2 strain) cultures were then exposed to the drug for 48 hours and the parasite viability 406 
was assessed by the pLDH method. 407 
bData are the mean IC50 (nM) ± SD of three different experiments in duplicate 408 
* p<0.05 vs fresh DHA; ** p<0.01 vs fresh DHA  409 
410 
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Table 6: Effect of ascorbic acid on DHA activity 411 
 control + Ascorbic acid 0.5mM + Ascorbic acid 1mM 
 IC50 (nM) b  Ratio IC50 
fresh 
DHA/IC50 
DHA after 
incubation 
IC50 (nM) Ratio IC50 
fresh 
DHA/IC50 
DHA after 
incubation 
IC50 (nM)  Ratio IC50 
fresh 
DHA/IC50 
DHA after 
incubation 
Fresh 
DHAa 
2.25 ± 0.3      
HbO 4.74 ± 
0.2** 
0,47 18.91 ± 6.1 0,12 >100  
HBCO 5.01 ± 
0.2** 
0,44 8.97 ± 0.6 0,25 17.79 ± 2.3  
Plasma 6.73 ± 2,3* 0,33 5.35 ± 2.3 0.42 5.57 ± 2 0.4 
aDHA (2µM) was used as fresh preparation or incubated for 3 hours in blood components in the 412 
presence of ascorbic acid. P. falciparum (W2 strain) cultures were then exposed to the drug for 48 413 
hours and the parasite viability was assessed by the pLDH method. 414 
bData are the mean IC50 (nM) ± SD of three different experiments in duplicate 415 
* p<0.05 vs fresh DHA; ** p<0.01 vs fresh DHA  416 




